Previous close | 0.0600 |
Open | 0.0600 |
Bid | 0.0100 |
Ask | 0.9000 |
Strike | 1.50 |
Expiry date | 2024-10-18 |
Day's range | 0.0600 - 0.0600 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Key Insights Institutions' substantial holdings in Novavax implies that they have significant influence over the...